| 000 | 01725 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513044839.0 | ||
| 264 | 0 | _c19950222 | |
| 008 | 199502s 0 0 eng d | ||
| 022 | _a0735-1097 | ||
| 024 | 7 |
_a10.1016/0735-1097(94)00368-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFaxon, D P | |
| 245 | 0 | 0 |
_aEffect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. _h[electronic resource] |
| 260 |
_bJournal of the American College of Cardiology _cFeb 1995 |
||
| 300 |
_a362-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aAspirin _xtherapeutic use |
| 650 | 0 | 4 |
_aCilazapril _xadministration & dosage |
| 650 | 0 | 4 | _aCoronary Angiography |
| 650 | 0 | 4 |
_aCoronary Disease _xdiagnostic imaging |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tJournal of the American College of Cardiology _gvol. 25 _gno. 2 _gp. 362-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0735-1097(94)00368-z _zAvailable from publisher's website |
| 999 |
_c7829132 _d7829132 |
||